Expression of HLA-A, HLA-DPB1, and lymphocyte marker LCK were analyzed in TCGA sarcoma subtypes to determine whether a significant loss of antigen presentation in UPS/MFS could limit efficacy of immunotherapies targeting MAGEA3. Here, MAGEA3 is linked to sarcoma.